INTRODUCING

Nobivac[®] NXT FeLV



DISCOVER NOBIVAC[®] NXT-LEVEL FeLV PROTECTION

The only non-adjuvanted feline leukemia vaccine with a 2-year duration of immunity (DOI)

Safeguard cats against FeLV with a revolutionary vaccine built on RNA particle technology.



Adjuvant-, preservative-, and thimerosal-free formulation



Proven 2-yr DOI



Low-volume 0.5-mL dose for a more gentle vaccine experience

Multi-layered immune activation

See how Nobivac[®] NXT technology works **>**







• • • • • • • • • • • • • • • • • •


Nobivac[®] NXT-level FeLV protection

	Nobivac [®] NXT FeLV	PUREVAX [®] FeLV
Proven 2-yr DOI	 Image: A set of the set of the	
Labeled effective against persistent viremia	 ✓ 	
Adjuvant-free formulation	×	×
Preservative-free formulation	✓	
Antibiotic-free formulation	×	
Low-volume (0.5-mL) dose	×	×

100%

of cats vaccinated with Nobivac® NXT FeLV were protected against persistent viremia in a clinical study.¹

Protection provided by vaccination



7 of 8 kittens in the control group became persistently antigenemic compared with 3 of 7 kittens in the PUREVAX® FeLV group and 0 of 8 kittens in the Nobivac® NXT FeLV group who received an initial vaccination series.^{1*}

Choose Nobivac[®] NXT for innovative FeLV protection.

Talk to your Merck Animal Health representative to learn more.

Technical Services: 1-800-224-5318 (Monday-Friday, 9:00 AM-6:00 PM ET)

Customer Service: 1-800-521-5767 (Monday-Friday, 9:00 AM-6:00 PM ET)



* Kittens were tested weekly from 3 to 12 weeks post challenge for the presence of antigenemia.

Reference: 1. Carritt K, Davis R, Stachura K, Mogler M, Xu Z, Tarpey I. An RNA particle vaccine expressing feline leukemia virus envelope protein protects against virulent FeLV challenge. Abstract presented at: ISCAID Symposium 2024; October 14-16, 2024; Vancouver, Canada.

All trademarks are property of their respective owners. Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-NOV-250100010 915704